Cancer Therapy News and Research

RSS

Researchers develop cheap, reliable diagnostic test for HLRCC

Researchers at the University of Oxford have developed a cheap and reliable diagnostic test for a rare form of cancer. The test involves screening tumour samples for a particular molecular fingerprint unique to this type of cancer.

21 May 2011

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

Virginia Commonwealth University researchers have found that nutrient supplementation, like the kind that is found in leafy greens, spinach and lettuce, may reduce the damage to the heart caused by a powerful anti-cancer drug.

20 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

Concord Medical first quarter total net revenues increase 14.7% to $13.3 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the first quarter ended March 31, 2011.

18 May 2011

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.

18 May 2011

New avenue for treating breast cancer

Researchers at the CHUM Research Centre and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

17 May 2011

Celgene, Foundation Medicine partner for clinical cancer genomic testing platforms

Foundation Medicine, Inc., a personalized cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine clinical care, today announced a strategic collaboration with Celgene Corporation.

17 May 2011

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

Cytori Therapeutics, Inc. (NASDAQ: CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have presented clinical outcomes using Adipose-Derived Regenerative Cell (ADRC) fat grafting in reconstructive breast surgery at the Association of Breast Surgery Conference in Manchester, UK, May 16-17, 2011. The procedure, referred to by Cytori as RESTORE, was separately investigated in Cytori’s own RESTORE 2 trial.

17 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Matthew Feddersen and Blake Marggraff from Lafayette, Calif. were awarded the top prize at the Intel International Science and Engineering Fair, a program of Society for Science & the Public. They received $75,000 and the Gordon E. Moore Award, in honor of the Intel co-founder and retired chairman and CEO, for developing a potentially more effective and less expensive cancer treatment that places tin metal near a tumor before radiation therapy.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Cancer Therapy News and Research

Researchers develop cheap, reliable diagnostic test for HLRCC

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

RTOG reports on largest trial for newly diagnosed glioblastoma

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

Concord Medical first quarter total net revenues increase 14.7% to $13.3 million

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

New avenue for treating breast cancer

Celgene, Foundation Medicine partner for clinical cancer genomic testing platforms

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Calypso System can precisely deliver radiation in post-prostatectomy patients

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Obese men may face high risk of prostate cancer progression

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News